20,000 Shares in Tyra Biosciences, Inc. $TYRA Bought by Elmind Capital LP

Posted by Brenda Bartman on Aug 26th, 2026

Elmind Capital LP bought a new position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA – Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 20,000 shares of the company’s stock, valued at approximately $638,800.

Other large investors have also bought and sold shares of the company. Hilton Head Capital Partners LLC bought a new stake in shares of Tyra Biosciences in the 1st quarter worth $30,000. Caitong International Asset Management Co. Ltd purchased a new position in Tyra Biosciences during the 4th quarter valued at approximately $51,000. Chung Wu Investment Group LLC bought a new position in Tyra Biosciences in the fourth quarter worth about $53,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Tyra Biosciences by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock worth $68,000 after acquiring an additional 534 shares during the period. Finally, State of Wyoming acquired a new stake in shares of Tyra Biosciences in the second quarter valued at about $76,000. 84.14% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TYRA has been the subject of a number of research reports. Bank of America lifted their price target on shares of Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Jefferies Financial Group restated a “buy” rating and issued a $42.00 price objective on shares of Tyra Biosciences in a research note on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a report on Friday, July 17th. Wolfe Research assumed coverage on Tyra Biosciences in a research note on Tuesday, May 19th. They issued a “peer perform” rating on the stock. Finally, JonesTrading initiated coverage on shares of Tyra Biosciences in a research report on Wednesday, June 17th. They set a “buy” rating and a $56.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $46.90.

View Our Latest Research Report on Tyra Biosciences

Tyra Biosciences Trading Down 4.3%

Tyra Biosciences stock traded down $1.12 during midday trading on Friday, hitting $25.01. 142,829 shares of the stock were exchanged, compared to its average volume of 873,719. The stock has a market capitalization of $1.49 billion, a price-to-earnings ratio of -10.42 and a beta of 0.77. The stock’s 50-day simple moving average is $29.58 and its 200 day simple moving average is $32.22. Tyra Biosciences, Inc. has a fifty-two week low of $11.70 and a fifty-two week high of $40.65.

Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). Equities analysts anticipate that Tyra Biosciences, Inc. will post -2.74 EPS for the current fiscal year.

Tyra Biosciences Company Profile

(Free Report)

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.